Head-To-Head Analysis: Leap Therapeutics (LPTX) & Its Rivals

Leap Therapeutics (NASDAQ: LPTX) is one of 289 public companies in the “Bio Therapeutic Drugs” industry, but how does it contrast to its peers? We will compare Leap Therapeutics to related businesses based on the strength of its profitability, institutional ownership, dividends, valuation, analyst recommendations, risk and earnings.

Insider & Institutional Ownership

1.0% of Leap Therapeutics shares are owned by institutional investors. Comparatively, 49.6% of shares of all “Bio Therapeutic Drugs” companies are owned by institutional investors. 58.4% of Leap Therapeutics shares are owned by company insiders. Comparatively, 16.9% of shares of all “Bio Therapeutic Drugs” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares Leap Therapeutics and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Leap Therapeutics N/A N/A -153.01%
Leap Therapeutics Competitors -5,441.68% -162.70% -35.92%

Analyst Ratings

This is a summary of current recommendations for Leap Therapeutics and its peers, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Leap Therapeutics 0 1 2 0 2.67
Leap Therapeutics Competitors 1131 3429 11928 241 2.67

Leap Therapeutics currently has a consensus target price of $15.50, suggesting a potential upside of 146.82%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 39.52%. Given Leap Therapeutics’ higher probable upside, equities analysts plainly believe Leap Therapeutics is more favorable than its peers.

Valuation and Earnings

This table compares Leap Therapeutics and its peers top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Leap Therapeutics N/A -$25.63 million -1.82
Leap Therapeutics Competitors $290.27 million $35.99 million 56.19

Leap Therapeutics’ peers have higher revenue and earnings than Leap Therapeutics. Leap Therapeutics is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Summary

Leap Therapeutics peers beat Leap Therapeutics on 8 of the 12 factors compared.

Leap Therapeutics Company Profile

Leap Therapeutics, Inc., formerly HealthCare Pharmaceuticals, Inc., is a clinical-stage biopharmaceutical company. The Company engages in acquiring and developing therapeutics in cancer biology. Its lead product candidates for use in clinical trials include TRX518 and DKN-01. DKN-01 is a monoclonal antibody targeting Dickkopf-related protein 1 (DKK1). TRX518 is a monoclonal antibody targeting the glucocorticoid-induced tumor necrosis factor-related receptor (GITR). DKN-01 has potential as a targeted cancer treatment in esophageal cancer, cholangiocarcinoma, non-small cell lung cancer, and other tumor types, such as pancreatic, gastric, liver, head and neck, uterine, and prostate cancers and multiple myeloma. It is conducting two clinical trials of TRX518 in patients with advanced solid tumors and have evidence of biomarker modulation and clinical activity. DKN-01 has been tested in a pilot study in patients with multiple myeloma in combination with lenalidomide and dexamethasone. .

Receive News & Ratings for Leap Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Leap Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply